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 Cellular migration is an integral component of many biological processes 
including immune function, wound healing and cancer cell metastasis. A complete model 
illustrating the mechanism by which cells accomplish movement is still lacking. Exploring 
the affects of various drugs on cell motility may be instrumental in discovering new 
proteins which mediate cell movement. This project aims ultimately to characterize the 
molecular target of the drug Cucurbitacin-I, a natural plant product. This drug has been 
shown to inhibit migration of epithelial sheets and may have anti-tumor activity. 
In this paper, we show that Cucurbitacin-I inhibits the migration of MDCK and 
B16F1 cells. The drug also affects the integrity of the actin cytoskeleton of these cells by 
indirectly stabilizing filamentous actin. Cucurbitacin-I does not, however, have an effect 
on the motility or cytoskeletal morphology of the soil amoeba, Dictyostelium discoidium.  
  
Introduction 
 Cellular motility is the basis for many important biological processes. Without it, 
life as we know it simply would not exist. Life’s dependence on cell migration begins 
during embryonic development. During this process, neurons travel along predetermined 
pathways within the embryo directed by chemical signals. In addition, mesenchymal 
cells disperse throughout the embryo to environments which allow them to differentiate 
into various tissues. Cell migration is also critical for immune function. Upon injury or 
infection, white blood cells are able to traverse the blood vessel endothelium and enter 
the surrounding tissue where they seek out and destroy bacterial invaders (1-3). On the 
other hand, cellular motility can have a pathological significance. Cancer cells are able to 
break away from the primary tumor and disseminate throughout the body. This process, 
known as metastasis increases the number of organs affected and greatly complicates 
treatment (4, 5). Because cell motility plays such a significant role both in health as well 
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as disease, it is important to understand how and why cells move. This knowledge may 
provide clues as to how cell motility can be inhibited or promoted. 
 Although research continues to make strides toward understanding how cells 
accomplish movement, a complete mechanism for cell migration is still lacking. Although 
the appearance of cell movement can differ slightly depending on cell type, current 
literature agrees on a basic model for migration. In this scheme, cells extend a thin 
membrane protrusion, known as a lamella, forward which is subsequently anchored to 
the extracellular matrix to provide the cell with traction. The rear of the cell is then 
retracted resulting in the translocation of the cell body. The efficacy of cell movement is 
based on how well a cell can couple protrusion and retraction (2, 4, 6, 7). An example of 
optimized coupling can be found in the fish epidermal keratocyte. This cell maintains a 
constant fan shape with a wide protruding lamella at the front while the cell body follows 
closely behind (8). During keratocyte locomotion, protrusion and retraction are closely 
coupled. In other cell types, such as fibroblasts, the front and the rear of the cell are not 
as closely coordinated. These cells accomplish movement through a slightly different 
mechanism. While keratocytes are mostly devoid of focal contacts, fibroblasts form focal 
adhesions in the front and rear of the cell. Fibroblasts first extend a lamella which is then 
anchored to the substrate through focal adhesions (8).  Once the protrusion is stabilized, 
adhesions at the rear of the cell are disassembled to allow the cell body to move 
forward. If these adhesions are not removed, they will either be torn from the substrate 
as the front of the cell moves forward or the cell will stop moving forward (9).  
 Cell shape and motility are ultimately dictated by a meshwork of filaments known 
collectively as the cytoskeleton. The cytoskeleton is composed of three major classes of 
protein including microtubules, microfilaments and intermediate filaments. Of these three 
components, actin microfilaments are primarily responsible for the motility machinery. 
Within the cell, actin exists as monomeric (G-actin) which is polymerized into filamentous 
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(F-actin). Actin filaments have inherent polarity and contain both a barbed and a pointed 
end. Lengthening of the filament can take place at either end, however polymerization  
occurs at a much faster rate at the barbed end and barbed ends are usually near the 
plasma membrane (8). As filaments elongate, protrusive force is generated and the 
membrane is pushed outward from the cell body. At first it seems counterintuitive that a 
filament which needs to add subunits in order to grow would be able to maintain enough 
contact to push a membrane forward. One theory for the mechanism of this occurrence 
is known as the tethered ratchet model. This model states that the actin filament is only 
transiently attached to the membrane. It is also possible that the filament never becomes 
attached to the membrane. Brownian motion causes fluctuations in the membrane, and if 
it deforms far enough, a new G-actin monomer will be able to join the end of the 
filament. This prevents the membrane from flexing back to its original shape and  must 
remain extended to accommodate the lengthened filament (10). The action of multiple 
filaments polymerizing in this manner results in membrane protrusion. Actin also 
provides the machinery for retraction of the rear of the cell. In some cell types, actin 
filaments in the rear of the cell are gathered into antiparallel bundles and slide past each 
other through the interaction with myosin II (8).  
 Actin filaments are capable of polymerizing in vitro in a solution of only adenosine 
triphosphate (ATP), actin monomers and salt. The filaments that form, however, are 
unable to interact with each other to form the elaborate actin structures found in the cell. 
This difference occurs because the cellular environment contains a number of proteins 
which regulate actin dynamics, known collectively as actin-binding proteins (ABPs). For 
example, ABPs can facilitate polymerization (profilin), sever filaments (cofilin), prevent 
severing (tropomyosin), bundle (alpha-actinin) or branch (Arp2/3) (4). The presence of 
different ABPs and different signaling pathways within the cell allow for the generation of 
vastly different actin structures within the same cell.  
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 Actin and its binding proteins are controlled through various upstream signaling 
pathways. A number of small guanosine triphosphatases (GTPases) including Rac, Rho 
and cdc42 have been widely implicated in regulating cell shape and motility (11). 
Differential protein activation determines which cellular structures will form.  For 
example, Rac promotes formation and extension of lamellae, Rho facilitates bundling of 
contractile actin bundles such as stress fibers and cdc42 is involved in filopod formation. 
These relationships have been derived mainly through overexpression experiments. For 
instance, overexpression of cdc42 results in the formation of numerous filopodia (6). 
Small GTPases also regulate other cell processes such as cell growth, cell-cell adhesion 
and cell adhesion to the ECM (2). Rac has been implicated in the formation of focal 
complexes within the lamella. These complexes are smaller and more dynamic than 
focal adhesions formed by Rho in the rear of the cell (11).  Differential regulation of cell 
shape and adhesion are crucial to successful cellular locomotion.   
 The plasticity of actin and its ABPs can be illustrated by comparing two major 
organelles of motility, the lamellipod and the filopod. Both structures are produced in the 
anterior portion of a cell’s leading edge during motility, however, they differ greatly in 
their underlying actin structures. The lamella is a thin protrusion, about 200nm thick, 
which is composed of a meshwork of polarized, branching actin filaments (4, 8). Barbed 
ends are oriented towards the anterior of the cell to facilitate protrusion. The branching 
of actin filaments within the lamella is due to the presence of the Arp2/3 complex which 
nucleates new filament branches off existing filaments. Arp2/3 not only induces 
polymerization of the new branch, but also caps the pointed end of the new branch to 
protect it from disassembly (4). Arp2/3’s role in actin nucleation has been supported by 
in vitro assays in which Arp2/3 is able to branch filaments and through immuno-electron 
micrographs of the lamella (7). In contrast, filopodia are thin hairlike membrane 
protrusions that extend past the cell edge and contain parallel bundles of actin held 
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together by actin bundling proteins such as fascin and fimbrin. Like lamellae, filopodia 
also harness the protrusive force of actin polymerization, but they do not contain Arp2/3 
and thus they do not branch (7). Filopodia and have been implicated in providing the cell 
with adhesions to the extracellular matrix because adhesion molecules such as cadherin 
and integrin localize to their tips. Filopodia are also thought to be a site for signal 
transduction and may play a role in steering during directed cell movement such as 
chemotaxis (6). During chemotaxis cells sense and move towards a gradient of 
chemoattractant molecules.  
 Advances continue to be made in the study of cellular motility. These strides can 
be attributed, in part, to the development of innovative assays which overcome the 
difficulties of researching cell locomotion. Actin rich structures such as lamellapodia and 
filopodia are difficult, if not impossible, to isolate from the cell (4). Therefore scientists 
have developed several model systems which are analogous to the leading edge of a 
cell. Scientists have replicated motility in a test tube containing only actin, Arp2/3 cofilin 
and capping protein. In this assay, activated beads are placed in the motility solution and 
are moved through the solution powered by the force of polymerizing actin. The assay 
can be tailored to study the effects of different ABPs on actin dynamics (10). 
 Pathogens have also been exploited in the study of cellular migration. 
Intracellular bacteria such as Listeria and Shigella propel themselves through the 
cytoplasm by polymerizing a comet tail of cellular actin (10). Listeria expresses a protein, 
Act A, located on its surface which is able to activate the Arp2/3 complex. Activated 
Arp2/3 recruits actin to polymerize behind the bacteria and hence propel it forward. This 
is analogous to actin driven lamellar protrusion. Recent studies have shown that Listeria 
construct two structurally different actin tails depending on the bacteria’s position within 
the cell. Listeria which protrude beyond the cell edge have long linear tails whereas 
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Listera within the cell have branching tails. This difference this thought to be due to 
differential ABP recruitment (4). 
Fluorescence microscopy has provided a way to study the dynamics of cellular 
motility in real time. Protein tags such as green fluorescent protein (GFP) and red 
fluorescent protein (RFP) can be conjugated to endogenous cellular proteins allowing 
researchers to track protein localization during locomotion. Multiple different proteins can 
be tracked at once if they are labeled with different tags. Light of a specific wavelength is 
used to excite each fluor. The images produced by each fluor can then be overlaid to 
determine how proteins localize in relation to one another. Fluorescence Speckle 
Microscopy (FSM) has been used to visualize treadmilling of actin filaments. During 
FSM, a small amount of fluorescently labeled actin is injected into a cell. The 
incorporation of the fluorescent monomers into F-actin is then tracked (8).  
The experiments previously discussed have focused on the study of single cell 
locomotion. Researchers have also investigated the dynamics of cell sheet migration. A 
common example of this occurs during epithelial wound healing. Wound closure may 
provide insight into the mechanism of cell movement because wound healing is driven 
by cell protrusion and morphological change rather then proliferation (2). Dr. Fenteany’s 
lab in UConn’s Chemistry department has utilized a wound healing assay to study cell 
motility. This technique has been used to screen chemical compounds to find those 
which effect cell sheet migration. A confluent sheet of Mandin-Darby Canine Kidney 
(MDCK) was grown to confluence and a reproducible wound was made in the 
monolayer. The rate of wound closure in the presence of compound was monitored and 
compared to a control compound-free wound (2). Compounds which increase the rate 
wound healing may have applications in treatment of slow healing wounds, especially 
those found in diabetic patients. Inhibitors of cell migration may be important in 
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preventing the metastasis of cancer cells (3). However, before a drug can be used in 
medicine, it is important to identify the compound’s molecular targets.  
Using the wound closure assay, the Fenteany lab has identified Cucurbitacin-I as 
an anti-migratory compound, but a complete list of its molecular targets is lacking. 
Cucurbitacins are a family of toxic, naturally occurring compounds which have been 
isolated from several plant species. The Cucurbitacins are divided in to twelve groups, 
denoted A through T, based on differences in molecular structure (12). Past research 
has found that the Cucurbitacins have anti-tumor, anti-inflammatory and analgesic 
effects (12, 13).  The anti-tumor activity of the Cucurbitacins was studied in the 1960’s, 
in hopes of finding a drug treatment for cancer, however, the cytotoxic affects of the drug 
seemed non-specific (12). Using various cell types as model systems, some 
Cucurbitacins have been found to inhibit proliferation, adhesion and to disrupt the actin 
cytoskeleton (14). 
More recently, research has identified Cucurbitacin-I as an inhibitor of the Janus 
activated kinase/signal transducer and activator of transcription (JAK/STAT-3) signaling 
pathway. JAK is a non-receptor tyrosine kinase which regulates the activity of STATs. 
STAT is a transcription factor which, when phosphorylated by JAK, will translocate to the 
nucleus where it will bind DNA and regulate transcription (14). Although there are 
several different STATs expressed in mammalian cells, Cucurbitacin-I specifically affects 
STAT-3. The JAK/STAT-3 pathway has been shown to affect cell proliferation and 
dedifferentiation (15). Interestingly, certain cancer cells have constitutively activated 
STAT-3. Animal research has indicated that blocking STAT-3 activation will inhibit tumor 
growth. Cucurbitacin-I decreases cellular levels of activated JAK and STAT-3 therefore 
lowering STAT-3 DNA binding. This effect suggests the Cucurbitacin-I may be usable as 
an anti-cancer drug. However specific molecular targets need to be defined before the 
drug can be fully exploited. Because JAK and STAT levels are both lowered, it is unlikely 
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that either protein is the target of the drug. Scientists are now considering upstream 
effectors of JAK as possible targets (14). JAK/STAT-3 has also been implicated as a 
mediator of cell migration, yet discrete evidence is still lacking (15). Somewhat less 
defined is Cucurbitacin-I’s effect on the actin cytoskeleton. It is unclear whether the 
drug’s affects on the JAK/STAT-3 pathway are independent of its affects on the 
cytoskeleton (13).  
My study utilizes several different cell types as model systems to investigate the 
effects of Cucurbitacin-I on cell migration and the cytoskeleton. MDCK epithelial cells 
were observed in sheets during wound healing and as single cells. B16-FI motile mouse 
melanoma cells were used to study the drug’s effects on single migrating cells. The drug 
was also screened for effects on Dictyostelium discoidium, a eukaryotic amoeba. In 
nature Dictyostelium can be found in soil feeding on bacteria. Dictyostelium has been 
used as a model system for studying many aspects of cell biology, including cell motility. 
Axenic strains of Dictyostelium have a short generation time and are easily maintained in 
broth media. Therefore Dictyostelium may be useful to screen for drugs which affect cell 





 Dictyostelium discoidium strain Ax2 transformed with a GFP-ABP120 fusion 
protein was grown in HL5 nutrient media at 21°C. Cells were provided by Dr. Knecht. 
 Madin Darby Canine Kidney (MDCK) epithelial cells transformed to express RFP-
actin were grown in Modified Eagle’s Medium containing 0.1% nonessential amino acids, 
ampicillin/streptomycin antibiotic and 10% FBS at 37C and 5%CO2. Cells were provided 
by Dr. Dani Janzen.  
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 B16F1 mouse melanoma cells transformed to express RFP-actin were grown in 
Delbucco’s Modified Eagles Medium with 0.1% D-glucose, 0.1% L-glutamine, amp/strep 
and 10% FBS at 37C and 5% CO2. Cells were provided by Dr. Dani Janzen. 
 All cells were passaged regularly upon reaching confluency.   
 
Drug Preparation and Storage 
A 10mM stock of Cucurbitacin dissolved in dimethlysulfoxide was obtained from 
the Fenteany lab. A 10uM working stock was prepared by adding 1ul drug to 1mL media. 
Drug was stored at -20C. Each experimental control solution contained the same 
amount of DMSO as the drug dilution.  
 
Microscopy/Imaging 
During imaging, mammalian cells were maintained at 37°C using a Bioptechs 
dish heater. Imaging was performed using a Zeiss widefield automated microscope. 
Time lapse images were acquired using Openlab software and subsequently compiled 
and analyzed using ImageJ. Motility was quantified using the ImageJ MTrackJ plug-in. 
 
Wound Healing Assay 
Bioptechs dishes were coated with 5ug/mL laminin. Five microliters 1ug/mL 
laminin solution was combined with 995ul phosphate buffered saline. 500ul of this 
solution was added to a single Biopechs dish. Dishes were then incubated at 37 degrees 
Celsius for one hour. A confluent plate of RFP-actin expressing MDCK cells were 
trypsinized and resuspended in 10mL MEM. One milliliter cell suspension containing 2 x 
10^5 cells/mL was placed into the Bioptechs dish. Cells were allowed to attach and form 
a confluent sheet overnight. Before imaging, cells were placed in 500ul HAMS bicarb-
free media containing 10% FBS. A single scratch wound was created in the monolayer 
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by scraping the surface of the dish with a 200ul pipette tip. The wound was then imaged 
for several hours. Then 500ul of medium containing 400nm Cucurbitacin-I was added to 
the dish to make a final concentration of 200nm Cucurbitacin-I. Images were taken for 
several more hours. Wound closure was evaluated based on rate of the wound over time 
before and after drug addition. Since the wound edge was not even, measurements from 
the top, middle and bottom of the wound were taken to evaluate degree of closure. The 
distance from one wound edge to the other at each of these three points were compared 
for closure during a two hour interval both with and without drug. These distances were 
converted to percentages by dividing the distance of wound closure by the width of the 
whole wound.   
 
Random Motility Assay 
Cells were plated on 5ul/mL laminin coated Bioptechs dishes at low density and 
allowed to settle overnight.  Imaging was done before and after drug addition. A 2x drug 
solution was added to existing cell media to bring the drug to the final concentration.   
 
Determination of G: F-actin ratio in vitro 
Actin seeds were formed by incubating G-actin overnight on ice (40ul 5x ISAP 
buffer, 20ul 20uM G-actin, 140ul distilled water). Actin was polymerized the next morning 
at ambient temperature for one hour (75ul actin seeds, 15 ul 5x ISAP buffer, 7.5 ul 20uM 
G-actin, 52.5ul distilled water). Four sample tubes were then set up, one containing 
200nm Jasplakinolide, one with 200nm Cucurbitacin-I and one with 1.6 uM Rhodamine 
Phalloidin stock and the last with no drug addition. Aliquots of 15ul polymerized actin 
were added to each tube and then the actin was diluted below the critical concentration 
by addition of depolymerization buffer (5mM Tris pH=7.8, 0.2mM CaCl2, 0.2mM ATP) to 
a final volume of 150ul. Tubes were incubated overnight at 4°C. Samples were 
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centrifuged in an airfuge for one hour, pellets resuspend in 20ul 2x sample buffer. Also, 
freshly polymerized actin was centrifuged in parallel. Samples were denatured in SDS 
sample buffer and loaded onto a 10% SDS-PAGE.  The gel was stained with GelCode 
Blue G-250 and destained in deionized water. 
 
Determination of G:F-actin ratio in vivo 
A confluent p100 plate of MDCK cells was trypsinized and split into a six well 
plate. The cells were allowed to settle for three to four hours. Three of the six wells were 
treated overnight with DMSO, Cucurbitacin-I and Jasplakinolode as indicated in Table 1. 
 5% DMSO 10 uM 
Cucurbitacin 
400x Jas MEM 
Control  80 ul - - 3.28 mL 
200 nm 
Curcurbitacin 
- 80ul - 3.28 mL 
200 nm 
Jasplakinolide 
80ul - 1 ul 3.28 mL 
Table 1 
Media was aspirated from each well and two milliliters drug media were added to wells 
one through three. The remaining drug dilutions were stored at -20C overnight and used 
to treat wells four through six the next morning. Following incubation the cells were 
harvested into 1.5 mL ependorf tubes and spun down at 5,000 rpm for five minutes. 
Supernatant was aspirated and cells were resuspended in 250 ul lysis buffer (50mM 
PIPIES pH=6.9, 50mM NaCl, 5mM MgCl2 5mM EGTA, 5% glycerol, 1% Triton-X, 0.1% 
NP-40, 0.1% Tween 20, 0.1% 2-mercaptoethanol, 1mM ATP, 1% PMSF, 1% TAME, 1% 
TPCK, 1% Aprotinin, 1% Pepstatin, 1% Chymostatin). Cells were incubated on ice for 30 
minutes. Samples were spun at 9,000 rpm for 10 minutes at 5°C. The supernatant (G 
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fraction) was removed and placed in a sterile 1.5 mL tube. The pellet (F fraction) was 
resuspended in 250ul lysis buffer. 250ul 2x loading buffer was added to each fraction. 
Samples were boiled at 100C for 5 minutes on a heat block. 15 ul of each sample was 
fractionated using a 10% SDS-PAGE gel. The protein was then electroblotted onto a 
nitrocellulose membrane at 12V for 2.5 hours in toulbin buffer (0.51% Tris, 1.9 % glycine, 
20% methanol). The membrane was blocked in non-fat dry milk for one hour, incubated 
in 1:500 mouse anti-actin antibody for one hour followed by one hour incubation in 
1:5000 goat anti-mouse conjugated with alkaline phosphatase. Development was 
examined using 22.5 mL development buffer (12g Tris Base, 095g MgCl2, 5.85g NaCl in 
one liter, pH 9.5), 2.5mL NitroBlue tetrazolium (1mg/mL in development buffer) and 2.5 
ul bcip (50mg/mL in DMSO). 
 
Data and Results 
Dr. Fenteany’s lab identified Cucurbitacin-I as an inhibitor of epithelial wound 
closure. His lab analyzed wounds for percent closure at low magnification. In order to 
gain more information about the nature of Cucurbitacin-I’s effect on the during wound 
closure, we wounded a monolayer of RFP-actin expressing MDCK cells and visualized 
the wound edges with a 40x oil objective. Using time lapse microscopy the wound could 
be seen closing slowly and steadily for two hours in the absence of drug. Upon drug 
addition, wound edge translocation was greatly inhibited within minutes. Cells at the 
wound edge seemed unable to move any further into the cleared area. As treatment 
continued, actin rich lamellae could still be seen extending from the cells on the wound 
edge into cleared zone. Over a two hour period in control media, about 21% wound 
closure occurred at a rate of about 0.45um/min. After the addition of 200nM 
Cucurbitacin-I, healing was visibly slowed within five minutes. During the two hour time 
interval following drug addition, the wound only closed by about 6% and the rate of 
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closure had been reduced 4.5x to 0.099um/min (Figures 1 and 2). Interestingly, after 
several hours incubation in drug the wound edge again began to migrate into the cleared 
area, however, instead of maintaining a confluent sheet, movement seemed 
uncoordinated. Cells capable of movement seemed to tear away from the sheet pulling 
the epithelial sheet behind them. These data support the observation that Cucurbitacin-I 
retards the rate of wound closure. The data also indicate that while cells can still 
protrude lamellae and some can still migrate, the cells are unable to coordinate wound 
closure.  
 We then explored the effects of Cucurbitacin-I on a different cell system and 
found that Cucurbitacin-I inhibits the translocation of B16F1 in a rapid and reversible 
manner (Fig. 1). When 250 nm Cucurbitacin-I was applied to migrating B16F1 cells, 
translocation ceased within five minutes. The cells appeared to freeze in place, while 
maintaining normal morphology. Although lamellae could be seen protruding from 
several cells, at low magnification we could not tell whether membrane ruffling was 
occurring during treatment. As drug incubation continued, the cells became increasingly 
rounded. Cells were left in drug for a total of 45 minutes. Upon removal of drug, cells 
continued to retract for about 30 minutes. The first cells began to regain movement one 
hour after drug removal. However, not all cells recovered at the same rate. Cells which 
were moving quickly and persistently before treatment were among the first to recover. 
Full recovery of the population occurred between four and five hours following drug wash 
out. Cucurbitacin-I does not affect the motility of Dictyostelium cells (data not shown). No 
difference in speed or morphology was seen at concentrations as high as 1.2uM.  
 Having shown that Cucurbitacin-I has a rapid and reversible effect on cellular 
translocation in B16F1 cells, we then looked more closely at the drug’s effect on the 
actin cytoskeleton. To do this, we imaged RFP-actin expressing B16F1 and MDCK cells 
in the presence of Cucurbitacin-I. We found that prolonged incubation in Cucurbitacin-I 
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caused actin aggregates to form MDCK cells (Fig. 3). Before drug addition, RFP-actin 
produces a diffuse signal throughout the cytoplasm. Areas of active actin polymerization, 
such as the lamellar edge produce a brighter signal; however no aggregation of actin is 
noted at this point. Upon addition of 200nM Cucurbitacin-I, cells cease translocation 
within minutes. However, cells are still able to extend lamellae during the first hour to 
hour and a half of treatment. This indicates that cells are still capable of actin 
polymerization in the early stages of drug treatment. After one and a half hours, cells 
cease lamellar extension, what appear to be stress fibers thicken and small punctate 
aggregates form throughout the cytoplasm. As treatment progresses, aggregates 
become larger while and cytoplasmic signal fades. By three and a half hours, cells have 
retracted all processes and the cells appear to have shrunken as they round up.  Upon 
removal of drug, cells begin to spread out, extend processes and within 12 hours, 
recover movement. After recovery, aggregates remain in the cytoplasm for several days. 
Similar actin aggregation is seen B16F1 cells in response to Cucurbitacin-I treatment. 
Figure 4 shows B16F1 cells which were treated in only 25nm Cucurbitacin-I. Aggregates 
form at about one hour. Aggregation continues throughout treatment, but effects are less 
severe, probably due to the lower concentration of drug. These data show that 
concentrations of Cucurbitacin-I as low as 25nm are able to effect cells. 
  Interestingly, Cucurbitacin-I did not cause actin aggregation in Dictyostelium 
(Fig. 5). It has been shown that actin aggregates do form in Dictyostelium in during 
treatment with actin stabilizing drug, Jasplakinolide. Cells remained motile despite 
treatment, but moved at a much slower rate compared to untreated cells (17). We 
wondered if Cucurbitacin-I was also causing actin stabilization. In an attempt learn more 
about the mechanism by which Cucurbitacin-I causes actin aggregation, we compared 
its effects to those of Jasplakinolide. Using RFP-actin expressing cells we determined 
that Jasplakinolide also causes actin aggregation in MDCK cells (Fig. 6). 
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Since Jasplakinolide treatment caused similar actin aggregates to form in MDCK 
cells we then tested to see if this drug would inhibit cellular translocation in a similar 
manner as Cucurbitacin-I. When a population of migrating B16F1 cells was treated with 
Jasplakinolide cells ceased translocation within five minutes (Fig. 7). Upon drug addition, 
cells appeared to freeze in place. As incubation continued, cells became retracted all 
processes and became rounded. Cells were incubated in drug for a total of two hours. 
As with Cucurbitacin-I, translocation resumes after drug removal. The first cells begin to 
resume migration with four hours of drug wash out. Recovery of the entire population is 
seen between eight and nine hours. A shorter recovery time was noted following 
Cucurbitacin-I treatment. It is possible that the cells took longer to recover from 
Jasplakinolide than Cucurbitacin-I because the cells were treated with Jasplakinolide for 
twice as long. 
Because treatment with Cucurbitacin-I and Jasplakinolide both caused similar 
effects on the actin cytoskeleton and gross motility, we wanted to determine if the two 
drugs were acting by the same mechanism. In order to explore this, we looked more 
closely at the effects of each drug on filamentous actin. Since Jasplakinolide is a known 
actin stabilizer, we wondered if Cucurbitacin-I was also stabilizing actin. To determine if 
this were true, we preformed an in vitro assay in which polymerized actin was treated 
with either Jasplakinolide or Cucurbitacin-I (Fig. 8). Each sample was then diluted in 
order to promote actin depolymerization.  While Jasplakinolide treated actin was 
stabilized despite dilution, Cucurbitacin-I treated actin depolymerized such that the 
resulting F-actin band resembled the negative control which contained untreated actin. 
These results indicate that unlike Jasplakinolide, Cucurbitacin-I does not directly 
stabilize actin filaments.  
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 Since fluorescence microscopy had shown that both drugs cause aggregation of 
F-actin, we explored the possibility that Cucurbitacin-I may be indirectly stabilizing actin 
filaments. We hypothesized that Cucurbitacin-I may acting on a protein within an actin 
regulatory pathway.  To test this hypothesis, we performed an in vivo assay to looking at 
the distribution of filamentous and monomeric actin within cells both before and after 
drug treatment. Healthy cells contain both F and G-actin. We hypothesized that if 
Cucurbitacin-I was stabilizing F-actin within cells, the cellular ratio between G and F-
actin pools would be shifted toward filamentous actin. Figure 9 shows the results of this 
experiment in which MDCK cells were incubated in growth medium, Jasplakinolide or 
Cucurbitacin-I. Cells were then assayed for their monomeric and filamentous actin 
content. Treated cells were lysed and the resulting suspension was centrifuged such that 
F-actin would precipitate while G-actin remained in suspension. F and G-actin fractions 
of cell lysate were run on a 10% acrylamine gel and actin bands were identified by 
western blot with an anti-actin antibody.   Cells treated overnight with Cucurbitacin-I and 
Jasplakinolide both contained a higher ratio of F to G-actin than did the control cells. 
While control cells contained a ratio of 0.52 F to G-actin, Jasplakinolide and Cucurbitacin 
treated cells contained ratios of 3.34 and 2.26, respectively. This experiment was 
repeated on cells incubated for only two hours in Cucurbitacin-I to determine if the shift 
in F-actin occurred earlier or later in treatment. We found there was still a shift from G to 
F-actin even at the two hour time point (Fig. 10) Control cells and Cucurbitacin-I treated 
cells have F to G-actin ratios of 0.19 and 2.49, respectively. This indicates that although 
the aggregates are not very large at two hours, there is still an increased amount of F-
actin within the cell.
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Discussion 
Previously published data has shown that Cucubitacin-I is an inhibitor of the 
JAK/STAT signal transduction pathway (14). This pathway ultimately regulates 
transcription factor binding to DNA. We have shown that Cucurbitacin-I is a potent 
inhibitor of cellular motility which also disrupts the actin cytoskeleton. Researchers have 
wondered whether Cucurbitacin-I’s effect on transcription is independent or 
interdependent of its effects on the actin cytoskeleton. It is well known that altering 
transcription takes hours to effect the cell. Our data has shown that inhibition of motility 
and the drug’s effects on the cytoskeleton occur within minutes of drug addition. This 
suggests that Cucurbitacin-I’s effect on transcription does not cause motility inhibition or 
cytoskeletal abnormalities. It is possible that Cucurbitacin-I’s disruption of the 
cytoskeleton may lead to transcriptional effects. It is probable that the two effects are 
both caused by one upstream target because it is unlikely that Cucubitacin-I binds to two 
different target molecules, one that controls transcription and one that regulates actin.  
One of the most striking cellular abnormalities observed during treatment with 
Cucurbitacin-I is the formation of large cytoplasmic actin aggregates. After about one 
hour of drug incubation, actin structures appear thicker throughout the cytoplasm. Some 
of these structures look similar to stress fibers.  As treatment continues these fibers 
seem to condense into aggregates. Once these aggregates have formed, they persist 
within the cell for several days after drug removal. It is tempting to think that these 
aggregates would cause a defect in cell motility, but that seems not to be the case. 
Interestingly, the inhibition of motility and formation of aggregates occur at drastically 
different time points during treatment. Inhibition of motility occurs within minutes while 
aggregate formation does not begin until at least one hour of treatment. This indicates 
that the aggregates themselves are not what cause the cells to cease translocation. In 
fact, our data has shown that cells will recover movement after drug removal while 
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cytoplasmic aggregates are still present. Thus the inhibition of motility is a short term 
and reversible effect whereas actin aggregation is a longer term effect which may be 
irreversible as complete clearance of aggregates was never observed.  
The rate of recovery from drug treatment seems to be dependent on the length of 
time in drug. B16F1 cells that have been treated for 30 minutes in Cucurbitacin-I recover 
movement within several hours. B16F1 cells that have been incubated in drug for three 
to four hours begin to recover around 12 hours after drug removal. This suggests the 
rate of recovery is dependent on the length of treatment. This time difference may occur 
because after several hours of treatment most celluar actin in sequestered in actin 
aggregates and therefore can not be used by the cell. Perhaps after actin aggregation 
has occurred, recovery is dependent on the synthesis of new G-actin. 
 In an attempt to further characterize the effects of Cucurbitacin-I, we compare its 
action to that of actin stabilizing drug, Jasplakinolide. Aggregates caused by 
Jasplakinolide are visually indistinguishable from those induced by Cucurbitacin-I. We 
have found that although both of these drugs have similar downstream effects, they do 
not act by the same mechanism. Our data has confirmed that while Jasplakinolide 
directly stabilizes F-actin, Cucurbitacin-I does not. We have shown that in contrast to 
Jasplakinolide, Cucurbitacin-I is incapable of stabilizing F-actin filaments in vitro. 
Interestingly, both drugs cause an apparent stabilization of F-actin in vivo. This may 
imply that Cucurbitacin-I’s target is a protein in a signaling pathway which is involved in 
actin regulation.  
 We have shown that cells are still capable of protrusion during the early stages of 
drug treatment. This suggests that Cucurbitacin-I does not inhibit actin polymerization. 
Conversely, it is possible that Cucurbitacin-I is interfering with the depolymerization of 
actin. Our in vivo data shows that Cucurbitacin-I causes an increase in the amount of F-
actin and a decrease in G-actin within cells. This may be because Cucurbitacin-I 
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prevents the depolymerization of existing actin filaments.  Since we know from in vitro 
data that Cucurbitacin-I does not directly interact with actin, it may be possible to 
conclude that the target of Cucurbitacin-I may lie somewhere within the regulatory 
pathway for depolymerization. Since the mechanism for actin depolymerization is not 
fully defined, it is difficult to speculate about which proteins in this mechanism may be 
affected.  
 Soil amoeba, Dictyostelium discoidium has provided us with further clues about 
Cucurbitacin-I’s action. Interestingly, Cucurbitacin-I does not have any apparent effect 
on Dictyostelium. Despite overnight incubation in 1.2uM drug, Dictyostelium do not show 
changes in motility or cytoskeletal morphology. Dictyostelium are often used as model 
systems for higher organisms because they contain many proteins which are 
homologous to mammalian proteins. The fact that Dictyostelium are not affected by 
Cucurbitacin-I suggests that the target of Cucurbitacin-I does not have a homolog in 
Dictyostelium. This information is consistent with our other data that Cucurbitacin-I does 
not directly stabilize actin because actin is a conserved protein in both cell systems. 
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Figure 1: Cucurbitacin-I Inhibits Epithelial Sheet Migration 
 
 RFP-actin expressing MDCK cells were plated and imaged as described in the 
materials and methods section. A single scratch wound was created in the monolayer 
and the wound edge was filmed for two hours without drug and then the media was 
changed to media containing 200nm Cucurbitacin-I. Cells were filmed for two additional 
hours. Images shown are a result of fluorescence imaging. Cells were exposed to 











Figure 2: Cucurbitacin-I Slows Rate of Wound Healing 
 
 Cells were prepped and imaged using same protocol as figure 1. This figure 
shows fluorescent images of MDCK RFP-actin cells during wound closure. There is a 
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Figure 3: Cucurbitacin-I reversibly inhibits motility of migrating B16F1 
 
B16-F1 cells were grown overnight on laminin coated Bioptechs dishes and then 
imaged at 37°C with a 10x objective. Cells were filmed for 45 minutes in the absence of 
drug and then drug was added and cells were filmed for an additional hour. Drug was 
then removed and cells were filmed until movement resumed. Tracks were added to 
images to follow movement during A) 45 minutes before drug B) 45 minutes drug 







Figure 3: Cucurbitacin-I causes actin aggregation in MDCK cells 
 
 MDCK RFP-actin cells were plated at low density in MEM media in laminin 
coated bioptechs dishes and allowed at attach overnight. Immediately before 
imaging MEM was replaced with 500ul HAMs bicarb free media containing 10% 
FBS. Cells were imaged before addition of drug (0 hr) and then 500ul additional 
media containing a 2x concentration of Cucurbitacin-I was added to the cells. 







Figure 4: Cucurbitacin-I causes Actin Aggregation in B16F1 Cells 
 
 Followed same procedure as in Figure 3 except RFP-actin B16F1 cells were 
treated with 25nm Cucburbitacin-I. These imaged were captured using fluorescence 
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Figure 5: Cucurbitacin-I does not affect the morphology of the Dictyostelium actin 
cytoskeleton 
 
 Dictyostelium cells transformed to express RFP ABD-120 were plated in p35 
dishes at low density in HL5 media and allowed to settle several hours. Cells were then 
placed in 1 ml of HL5 containing A) 0.25% DMSO B) 100nm Cucurbitacin 0.25% DMSO 
and C) 1250nM Cucurbitacin, 0.25% DMSO. Cells were incubated overnight at 21 
degrees Celsius and imaged the following morning. Several still shots were taken of 





















are needed to see this picture.
 
Figure 6: Jasplakinolide causes similar cytoskeletal changes in MDCK cells as 
Cucurbitacin-I 
 
 Cells were prepared and imaged as in figure except 200nm Jasplakinolide was 




Figure 7: The actin stabilizer, Jasplakinolide, also reversibly inhibits 
cellular motility 
  
B16-F1 cells were plated and imaged as indicated in Figure 2 except Jasplakinolide was 
used.  A) Cells are spread and moving before drug addition B) Cells are rounded 
following one hour in drug C) Cells spread out again and resume movement 9 hours 
after drug removal. The results show that like Cucurbitacin-I, Jasplakinolide also rapidly 









Figure 8: Cucurbitacin-I does not directly stabilize actin filaments 
 
 Purified human actin was polymerized and then B) pelleted immediately 
without the addition of destabilization buffer C) incubated overnight in 
destabilization buffer only D) incubated overnight in destabilization buffer 
containing 200nM Jasplakinolide and E) incubated overnight in destabilization 
buffer containing 200nM Cucurbitacin-I .  Pellets were solubilized in SDS sample 
buffer and run on 10% polyacrylamide gel.  The gel was stained with GelCode 
Blue G-250 comasssie blue stain to visualize the actin band. Lane A contains 








Figure 9: Cucurbitacin-I plays a role in the stabilization of actin filaments in 
vivo 
 
 Confluent sheets of RFP-actin MDCK cells were incubated in DMSO 
control media, 200nm Jasplakinolide or 200nm Cucurbitacin overnight. Cells 
were harvested, lysed and the lysate was spun down to separate G actin from 









Figure 10: A Shift to F-actin is seen after short term Cucurbitacin-I treatment 
 
 Followed same procedure as in Figure 9 except cells were incubated in 
200 nm Cucurbitacin-I for two hours rather than overnight. A) Control cell G-actin B) 
control cell F-actin C) Cucurbitacin-I treated cells G-actin D) Cucurbitacin-I treated cells 
F-actin. This result shows that the shift to F-actin in Cucurbitacin-I treated cells occurs 
early in drug treatment. 
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